US Court Affirms Favorable Ruling for Sun Pharma in Lipitor Patent Litigation

Sun Pharmaceutical Industries and its subsidiaries have received a favorable ruling from the US Court of Appeals for the Third Circuit in antitrust litigation related to a 2008 patent settlement with Pfizer over generic Lipitor. The court affirmed summary judgment in favor of Sun Pharma and denied class certification to the plaintiffs, effectively resolving the long-standing case. The decision marks a significant development, substantially closing the litigation, though plaintiffs may still seek further remedies under applicable law.